BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome. Drugs. 2013;73:2053-2066. [PMID: 24249647 DOI: 10.1007/s40265-013-0147-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Qiao Q, Teng X, Wang N, Lu R, Guo L, Zhang X, Du Y, Wang W, Chen S, Wu Q, He G, Wang Y, Hu W. A novel CRIg-targeted complement inhibitor protects cells from complement damage. FASEB J 2014;28:4986-99. [PMID: 25114177 DOI: 10.1096/fj.14-258046] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
2 Konar M, Granoff DM. Eculizumab treatment and impaired opsonophagocytic killing of meningococci by whole blood from immunized adults. Blood 2017;130:891-9. [PMID: 28630122 DOI: 10.1182/blood-2017-05-781450] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 11.2] [Reference Citation Analysis]
3 Dhillon S. Eculizumab: A Review in Generalized Myasthenia Gravis. Drugs 2018;78:367-76. [PMID: 29435915 DOI: 10.1007/s40265-018-0875-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 13.0] [Reference Citation Analysis]
4 Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061-1073. [PMID: 25651368 DOI: 10.1038/ki.2014.423] [Cited by in Crossref: 234] [Cited by in F6Publishing: 194] [Article Influence: 33.4] [Reference Citation Analysis]
5 Macia M, de Alvaro Moreno F, Dutt T, Fehrman I, Hadaya K, Gasteyger C, Heyne N. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10:310-319. [PMID: 28621343 DOI: 10.1093/ckj/sfw115] [Cited by in Crossref: 8] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
6 Melis JP, Strumane K, Ruuls SR, Beurskens FJ, Schuurman J, Parren PW. Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics. Mol Immunol 2015;67:117-30. [PMID: 25697848 DOI: 10.1016/j.molimm.2015.01.028] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 11.4] [Reference Citation Analysis]
7 Frampton JE. Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder. Drugs 2020;80:719-27. [PMID: 32266705 DOI: 10.1007/s40265-020-01297-w] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
8 Tiller G, Lammerts RGM, Karijosemito JJ, Alkaff FF, Diepstra A, Pol RA, Meter-arkema AH, Seelen MA, van den Heuvel MC, Hepkema BG, Daha MR, van den Born J, Berger SP. Weak Expression of Terminal Complement in Active Antibody-Mediated Rejection of the Kidney. Front Immunol 2022;13:845301. [DOI: 10.3389/fimmu.2022.845301] [Reference Citation Analysis]
9 Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 2017;30:127-34. [PMID: 26995002 DOI: 10.1007/s40620-016-0288-3] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 7.5] [Reference Citation Analysis]
10 Shi J, Rose EL, Singh A, Hussain S, Stagliano NE, Parry GC, Panicker S. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood 2014;123:4015-22. [DOI: 10.1182/blood-2014-02-556027] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 10.0] [Reference Citation Analysis]
11 Bozio CH, Isenhour C, McNamara LA. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States. PLoS One 2020;15:e0241989. [PMID: 33180804 DOI: 10.1371/journal.pone.0241989] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Bao L, Cunningham PN, Quigg RJ. Complement in Lupus Nephritis: New Perspectives. Kidney Dis (Basel) 2015;1:91-9. [PMID: 27536669 DOI: 10.1159/000431278] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 5.9] [Reference Citation Analysis]
13 Jin A, Boroujerdi-Rad L, Shah G, Chen JL. Thrombotic microangiopathy and human immunodeficiency virus in the era of eculizumab. Clin Kidney J 2016;9:576-9. [PMID: 27478600 DOI: 10.1093/ckj/sfw035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
14 Agudo I, Souto-Moura T, Azevedo L, Cavaco R, Germano N, Bento L. Atypical hemolytic uremic syndrome in intensive care: Case report in an adult. Med Intensiva 2016;40:188-90. [PMID: 26596222 DOI: 10.1016/j.medin.2015.09.007] [Reference Citation Analysis]
15 Kambhampati S, Park W, Habtezion A. Pharmacologic therapy for acute pancreatitis. World J Gastroenterol 2014; 20(45): 16868-16880 [PMID: 25493000 DOI: 10.3748/wjg.v20.i45.16868] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 31] [Article Influence: 4.5] [Reference Citation Analysis]
16 Apostolidis SA, Sarkar A, Giannini HM, Goel RR, Mathew D, Suzuki A, Baxter AE, Greenplate AR, Alanio C, Abdel-Hakeem M, Oldridge DA, Giles J, Wu JE, Chen Z, Huang YJ, Pattekar A, Manne S, Kuthuru O, Dougherty J, Weiderhold B, Weisman AR, Ittner CAG, Gouma S, Dunbar D, Frank I, Huang AC, Vella LA, Reilly JP, Hensley SE, Rauova L, Zhao L, Meyer NJ, Poncz M, Abrams CS, Wherry EJ; UPenn COVID Processing Unit. Signaling through FcγRIIA and the C5a-C5aR pathway mediates platelet hyperactivation in COVID-19. bioRxiv 2021:2021. [PMID: 33972943 DOI: 10.1101/2021.05.01.442279] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Bao L, Cunningham PN, Quigg RJ. The complement system in lupus nephritis. F1000Res 2015;4:145. [DOI: 10.12688/f1000research.6562.1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Keating GM. Eculizumab: a guide to its use in atypical haemolytic uraemic syndrome. Drugs Ther Perspect 2014;30:166-72. [DOI: 10.1007/s40267-014-0120-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Hess C, Kemper C. Complement-Mediated Regulation of Metabolism and Basic Cellular Processes. Immunity 2016;45:240-54. [PMID: 27533012 DOI: 10.1016/j.immuni.2016.08.003] [Cited by in Crossref: 73] [Cited by in F6Publishing: 65] [Article Influence: 14.6] [Reference Citation Analysis]
20 Melton-Celsa AR, Carvalho HM, Thuning-Roberson C, O'Brien AD. Protective efficacy and pharmacokinetics of human/mouse chimeric anti-Stx1 and anti-Stx2 antibodies in mice. Clin Vaccine Immunol 2015;22:448-55. [PMID: 25716230 DOI: 10.1128/CVI.00022-15] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Jodele S, Fukuda T, Mizuno K, Vinks AA, Laskin BL, Goebel J, Dixon BP, Chima RS, Hirsch R, Teusink A, Lazear D, Lane A, Myers KC, Dandoy CE, Davies SM. Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 2016;22:307-15. [PMID: 26456258 DOI: 10.1016/j.bbmt.2015.10.002] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 11.7] [Reference Citation Analysis]
22 Walsh TL, Bean HR, Kaplan RB. Neisseria cinerea bacteremia in a patient receiving eculizumab: a case report. Infection 2018;46:271-4. [DOI: 10.1007/s15010-017-1090-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
23 Liszewski MK, Atkinson JP. Complement regulators in human disease: lessons from modern genetics. J Intern Med 2015;277:294-305. [PMID: 25495259 DOI: 10.1111/joim.12338] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 5.9] [Reference Citation Analysis]
24 Sharp JA, Whitley PH, Cunnion KM, Krishna NK. Peptide inhibitor of complement c1, a novel suppressor of classical pathway activation: mechanistic studies and clinical potential. Front Immunol 2014;5:406. [PMID: 25202312 DOI: 10.3389/fimmu.2014.00406] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
25 Contreras E, de la Rubia J, Del Río-Garma J, Díaz-Ricart M, García-Gala JM, Lozano M; Grupo Español de Aféresis. [Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group]. Med Clin (Barc) 2015;144:331.e1-331.e13. [PMID: 25433791 DOI: 10.1016/j.medcli.2014.09.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
26 van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advances. F1000Res 2016;5:F1000 Faculty Rev-2515. [PMID: 27803798 DOI: 10.12688/f1000research.8971.1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
27 Monteleone JPR, Gao X, Kleijn HJ, Bellanti F, Pelto R. Eculizumab Pharmacokinetics and Pharmacodynamics in Patients With Generalized Myasthenia Gravis. Front Neurol 2021;12:696385. [PMID: 34795626 DOI: 10.3389/fneur.2021.696385] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Bordron A, Bagacean C, Tempescul A, Berthou C, Bettacchioli E, Hillion S, Renaudineau Y. Complement System: a Neglected Pathway in Immunotherapy. Clin Rev Allergy Immunol 2020;58:155-71. [PMID: 31144209 DOI: 10.1007/s12016-019-08741-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
29 Tammam SN, El Safy S, Ramadan S, Arjune S, Krakor E, Mathur S. Repurpose but also (nano)-reformulate! The potential role of nanomedicine in the battle against SARS-CoV2. J Control Release 2021;337:258-84. [PMID: 34293319 DOI: 10.1016/j.jconrel.2021.07.028] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Ferreira E, Oliveira N, Marques M, Francisco L, Santos A, Carreira A, Campos M. Eculizumab for the treatment of an atypical hemolytic uremic syndrome with mutations in complement factor I and C3. Nefrologia 2016;36:72-5. [PMID: 26541438 DOI: 10.1016/j.nefro.2015.07.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]